Intent-to-Treat Analysis of Liver Transplant for Hepatocellular Carcinoma in the MELD Era: Impact of Hepatitis C and Advanced Status

Digestive Diseases and Sciences

Volumn 59, Issue 12, 2014, Pages 3062-3072

  Hu, Zhenhua ^a   Li, Zhiwei ^a   Xiang, Jie ^a   Zhou, Jie ^a   Yan, Sheng ^a   Wu, Jian ^a   Zhou, Lin ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Liver transplantation; Patient selection; Primary hepatic malignancy; Registry; Waiting list

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; LIVER FAILURE; LIVER NEOPLASMS; MIDDLE AGED; SURVIVAL; TIME;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; WAITING LISTS;

EID: 84912144944     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3266-4     Document Type: Article

References (36)

1. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin N Am. 2010;24:899–919.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.
3. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann NY Acad Sci. 2002;963:13–20.
4. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744–749.
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832.
6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.
7. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007; 246:502–509; discussion 9–11.
8. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403.
9. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–1732.
10. Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001–1007.
11. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896.
12. Melum E, Friman S, Bjoro K, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol. 2007;47:777–783.
13. Levine GN, McCullough KP, Rodgers AM, Dickinson DM, Ashby VB, Schaubel DE. Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant. 2006;6:1228–1242.
14. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783–790.
15. Dutkowski P, Oberkofler CE, Bechir M, et al. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl. 2011;17:674–684.
16. Weismuller TJ, Fikatas P, Schmidt J, et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany—limitations of the ‘sickest first’-concept. Transpl Int. 2011;24:91–99.
17. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44–S57.
18. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13:391–399.
19. Kwon CH, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis. 2007;25:313–319.
20. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832–838.
21. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–2063.
22. Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–722.
23. Jain D, Nayak NC, Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol. 2012;24:840–843.
24. Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci. 2011;56:276–278.
25. Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:168–174.
26. Roayaie S, Haim MB, Emre S, et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol. 2000;7:764–770.
27. Waki K, Sugawara Y, Tamura S, et al. Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data. Transplantation. 2011;92:809–814.
28. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012;56:149–156.
29. Berg CL, Steffick DE, Edwards EB, et al. Liver and intestine transplantation in the United States 1998–2007. Am J Transplant. 2009;9:907–931.
30. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232:490–500.
31. Steinmuller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17:138–144.
32. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl. 2002;8:736–748.
33. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–819.
34. Bozorgzadeh A, Orloff M, Abt P, et al. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transpl. 2007;13:807–813.
35. Schmitt TM, Kumer SC, Shah N, Argo CK, Northup PG. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Ann Hepatol. 2010;9:390–396.
36. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–684.